Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Assets (2023 - 2025)

Historic Assets for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $231.3 million.

  • Compass Therapeutics' Assets rose 5505.03% to $231.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.3 million, marking a year-over-year increase of 5505.03%. This contributed to the annual value of $140.4 million for FY2024, which is 1050.01% down from last year.
  • Per Compass Therapeutics' latest filing, its Assets stood at $231.3 million for Q3 2025, which was up 5505.03% from $116.7 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Assets high stood at $231.3 million for Q3 2025, and its period low was $116.7 million during Q2 2025.
  • For the 3-year period, Compass Therapeutics' Assets averaged around $161.8 million, with its median value being $156.9 million (2023).
  • Examining YoY changes over the last 5 years, Compass Therapeutics' Assets showed a top increase of 5505.03% in 2025 and a maximum decrease of 2500.66% in 2025.
  • Compass Therapeutics' Assets (Quarter) stood at $156.9 million in 2023, then decreased by 10.5% to $140.4 million in 2024, then soared by 64.71% to $231.3 million in 2025.
  • Its Assets was $231.3 million in Q3 2025, compared to $116.7 million in Q2 2025 and $131.5 million in Q1 2025.